Last Updated: 06 Nov 2024
Executive Summary
Aspira Women's Health Inc. (AWH) is a medical diagnostics company focusing on women's health. With a market capitalization of $13.88 million, AWH has experienced revenue growth of -0.027% year-over-year and an EPS of -$1.38. Despite a negative EBITDA of -$17.22 million and a trailing PE of none, analysts have a buy rating on the stock with a target price of $4.25.
Company Overview
Aspira Women's Health Inc. develops and markets diagnostic solutions for gynecologic health. Headquartered in Austin, Texas, the company's products aim to improve women's health outcomes.
Fundamental Analysis
Revenue: AWH reported revenue of $8.92 million in the trailing twelve months (TTM), reflecting a modest decline of -0.027% year-over-year.
Profitability: The company's profitability metrics are weak, with a gross profit margin of -1.788%, an operating margin of -1.813%, and a net income margin of -1.857%.
Earnings Per Share (EPS): AWH reported an EPS of -$1.38 in the TTM, indicating a loss per share.
Book Value: The company's book value per share is -$0.289, suggesting that the market value is significantly higher than the company's net assets.
Technical Analysis
52-Week High/Low: AWH's stock price has ranged between $5.65 and $0.738 in the past 52 weeks.
Moving Averages: The 50-day moving average is $0.885, while the 200-day moving average is $2.309.
Beta: The beta of 1.467 indicates that AWH's stock is more volatile than the overall market.
Short Term Outlook
In the short term, AWH's stock may face challenges due to its weak profitability and negative EPS. However, the company's revenue growth and analyst buy rating could provide some support.
Long Term Outlook
The long-term outlook for AWH depends on its ability to improve its profitability and execute its growth strategy. If the company can successfully address these challenges, it could potentially see a recovery in its stock price.
Analyst Recommendations
Analysts have a buy rating on AWH, with a target price of $4.25. This suggests that analysts believe the stock is undervalued and has potential for growth.
